IRIS
GENTILE, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.237
AS - Asia 857
EU - Europa 751
AF - Africa 15
OC - Oceania 1
SA - Sud America 1
Totale 2.862
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.233
CN - Cina 474
IT - Italia 463
SG - Singapore 346
FI - Finlandia 86
DE - Germania 75
AT - Austria 38
NL - Olanda 31
KR - Corea 15
GB - Regno Unito 14
CZ - Repubblica Ceca 11
FR - Francia 8
SN - Senegal 7
UA - Ucraina 7
HK - Hong Kong 4
ZA - Sudafrica 4
IN - India 3
PA - Panama 3
AZ - Azerbaigian 2
ET - Etiopia 2
IE - Irlanda 2
JP - Giappone 2
LA - Repubblica Popolare Democratica del Laos 2
PH - Filippine 2
PT - Portogallo 2
RO - Romania 2
SA - Arabia Saudita 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
CA - Canada 1
CL - Cile 1
DK - Danimarca 1
ES - Italia 1
GR - Grecia 1
HU - Ungheria 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
PK - Pakistan 1
PL - Polonia 1
SE - Svezia 1
SI - Slovenia 1
TW - Taiwan 1
Totale 2.862
Salva come PNG Salva come JPEG
Città #
Boardman 641
Florence 261
Singapore 251
Shanghai 207
Helsinki 74
Ashburn 68
Ogden 68
Sesto Fiorentino 47
Noto 45
Munich 40
Vienna 32
Guangzhou 27
Wuhan 27
Los Angeles 23
New York 23
Chandler 19
Washington 19
Beijing 17
Seoul 15
Amsterdam 14
Naaldwijk 14
Rome 13
Lappeenranta 12
Jinhua 9
Rende 9
Dakar 7
Santa Clara 7
Yiwu 7
Seattle 6
Wuxi 6
Bari 5
Jiaxing 5
Kilburn 5
Milan 5
Chicago 4
Cosenza 4
London 4
Naples 4
Zibo 4
Brooklyn 3
Dalian 3
Falkenstein 3
Frankfurt am Main 3
Genoa 3
Hong Kong 3
Lawrence 3
Nuremberg 3
Palmi 3
Paris 3
Roxbury 3
Sassari 3
Addis Ababa 2
Ann Arbor 2
Baku 2
Bologna 2
Borgomanero 2
Bratislava 2
Bucharest 2
Dublin 2
Gualdo Tadino 2
Heze 2
Jining 2
Manila 2
Mestre 2
Miami 2
Nantong 2
Newark 2
Ningbo 2
Paola 2
Pomigliano d'Arco 2
Raipur 2
Riyadh 2
Romainville 2
San Francisco 2
Shenzhen 2
Tokyo 2
Torano Castello 2
Turin 2
Vientiane 2
West Jordan 2
Athens 1
Bremen 1
Cascina 1
Catania 1
Central 1
Chizhou 1
Cirò Marina 1
Clifton 1
Cologne 1
Colombo 1
Debrecen 1
Des Moines 1
Dipignano 1
Forest City 1
Foshan 1
Fuzhou 1
Hamm 1
Hangzhou 1
Harbin 1
Inglewood 1
Totale 2.162
Salva come PNG Salva come JPEG
Nome #
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 79
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 46
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 34
A novel phage display based platform for exosome diversity characterization 33
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 32
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 32
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 31
Elotuzumab in multiple myeloma 31
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 30
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 29
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 29
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 29
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 28
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? 28
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 28
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 27
Teclistamab-cqyv in multiple myeloma 27
Iron chelation therapy 26
Belantamab mafodotin in multiple myeloma 26
Myelodysplastic syndromes with ring sideroblasts 24
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 24
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 24
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 24
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 24
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 24
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. 24
Cerebral pheohyphomycosis due to curvularia species 23
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 23
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 23
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 23
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 23
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 23
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 23
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 22
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 22
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 22
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 22
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 22
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 22
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 22
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 21
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 21
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 21
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 20
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity 20
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma 20
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 19
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 19
Acalabrutinib in chronic lymphocytic leukemia 19
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 19
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 18
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. 18
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant 18
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations 18
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 17
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary Immune Thrombocytopenia: a randomised trial 17
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 17
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 17
An old drug with a new future: bendamustine in multiple myeloma 17
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) 16
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 16
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 16
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 16
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. 16
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 16
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 16
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. 16
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy 15
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 15
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients 15
Ivosidenib in acute myeloid leukemia 15
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey 15
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. 15
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 15
Editorial: Lymphoid cells and tumor microenvironment: a functional crosstalk 15
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 15
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay 15
The use of ibrutinib before and after allogeneic stem cell transplantation 14
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment 14
Glasdegib for the treatment of acute myeloid leukemia 14
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 14
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 14
Isatuximab in multiple myeloma 14
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. 14
An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. 14
Momelotinib in myelofibrosis 14
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 14
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 13
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 13
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 13
Selinexor in multiple myeloma 12
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 12
A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI) 12
Zanubrutinib for the treatment of chronic lymphocytic leukemia 12
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 12
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 11
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 11
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: iLeukemia 11
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 11
Le complicanze infettive nella leucemia linfatica cronica 11
Totale 2.036
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 4 2 0 0 0 1 0 1 0 0
2021/202224 0 2 0 0 2 0 0 6 1 1 5 7
2022/2023442 6 5 3 11 8 5 279 22 19 20 50 14
2023/20241.536 35 36 245 194 97 153 80 48 120 50 67 411
2024/20251.154 179 611 112 151 101 0 0 0 0 0 0 0
Totale 3.164